T14 Stock Overview
Produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥2.23 |
| 52 Week High | CN¥2.66 |
| 52 Week Low | CN¥1.66 |
| Beta | 0.78 |
| 11 Month Change | -8.98% |
| 3 Month Change | 3.72% |
| 1 Year Change | 10.40% |
| 33 Year Change | 116.50% |
| 5 Year Change | 167.07% |
| Change since IPO | 400.77% |
Recent News & Updates
Recent updates
Is Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) A Risky Investment?
Nov 03
Is Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14) Expensive For A Reason? A Look At Its Intrinsic Value
Aug 08Should You Be Adding Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) To Your Watchlist Today?
Jul 21We Think Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Can Manage Its Debt With Ease
Jun 20If EPS Growth Is Important To You, Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Presents An Opportunity
Apr 17Calculating The Intrinsic Value Of Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SGX:T14)
Mar 01Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Has A Pretty Healthy Balance Sheet
Feb 03Shareholder Returns
| T14 | SG Pharmaceuticals | SG Market | |
|---|---|---|---|
| 7D | -4.3% | -0.9% | -0.02% |
| 1Y | 10.4% | 7.2% | 13.9% |
Return vs Industry: T14 exceeded the SG Pharmaceuticals industry which returned 7.2% over the past year.
Return vs Market: T14 underperformed the SG Market which returned 13.9% over the past year.
Price Volatility
| T14 volatility | |
|---|---|
| T14 Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 6.2% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in SG Market | 14.8% |
| 10% least volatile stocks in SG Market | 2.2% |
Stable Share Price: T14 has not had significant price volatility in the past 3 months compared to the SG market.
Volatility Over Time: T14's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 4,619 | Lei Wang | www.jydrt.com.cn |
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and other products primarily in the People’s Republic of China. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; and biochemical pharmaceutical products, as well as wholesale and retail sale of medicines. Its products include Suxiao Jiuxin Pills, Jingwanhong Ointment, Biqi Capsules, Shunaoxin Dropping Pills, Zilongjin Tablets, Qingfei Xiaoyan Pills, Huoxiangzhengqi Soft Capsules, Tongmai Yangxin Pills, Weichangan Pills, Qingyan Dropping Pills, Haima Bushen Pills, Angong Niuhuang Pills, Niuhuang Qingxin Pills, Qinggong Shoutao Pills, etc. The company also engages in pharmaceutical commercial logistic services; pharmaceuticals retail; chemical raw materials and preparations; and biomedicine.
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited Fundamentals Summary
| T14 fundamental statistics | |
|---|---|
| Market cap | US$2.97b |
| Earnings (TTM) | US$128.64m |
| Revenue (TTM) | US$1.11b |
26.5x
P/E Ratio3.1x
P/S RatioIs T14 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T14 income statement (TTM) | |
|---|---|
| Revenue | CN¥8.04b |
| Cost of Revenue | CN¥4.30b |
| Gross Profit | CN¥3.74b |
| Other Expenses | CN¥2.81b |
| Earnings | CN¥932.37m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.21 |
| Gross Margin | 46.50% |
| Net Profit Margin | 11.60% |
| Debt/Equity Ratio | 19.8% |
How did T14 perform over the long term?
See historical performance and comparison